Fri, Oct 31, 2014, 1:31 AM EDT - U.S. Markets open in 7 hrs 59 mins


% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • mtdsus mtdsus Oct 3, 2012 6:36 PM Flag

    Omocor-Lovaza launch by Joe Z and Paul Huff in 2005

    Omacor(original name-changed to Lovaza in July 2007 at FDA request) was launched by Joe Zakrzewski and Paul Huff. They achieved:
    2005 sales close to 150mil.$
    2006 sales 300 mil.$
    2007 Sales 500 mil.$ -- GSK press release said 341 mil.$ in 9 months of 2007--an increase of 62% over the same period in 2006.
    2011 Sales--900mil.$
    Now tell me -DO YOU CONSIDER this a GOOD LAUNCH or Bad launch?

    What's my point: Amarin senior management is capable of launching VASCEPA by themselves.
    GSK did not do any wonders by moving sales from 500mil.$ in 2007 to 900mil.$ in 2011.

    Look at VERTEX--vs.Merck for Hep.C drug.
    Although Merck got approval 3 weeks earlier from FDA, Vertex hit the road so fast that it achieved over 700 mil.$ sales in 5 months and 1.6 bil.$ next year.
    TRUST me-- MERCK,GSK are bureaucratic co.--slow to make decisions.
    If they launched VASCEPA--Sales growth will be slower.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lovaza is a superior product with extremely attractive economics and had no competetion.

      Vascepa is a inferior product wich will be at least twice as expensive to produce, will have no real protection AND extreme competetion FROM big pharma AND generics from 2015.

      Joe Z came to Reliant AFTER the Lovaza rights where aquired and left BEFORE the company was sold to GSK!

      And the 341 million $ in sales was for ALL Reliants products you #$%$ and they also had almost 900 reps to achive those sales!!

    • Based on Actual facts, Small co.are fast on feet with less bosses to review every decision.Large co.have too many bosses to MICROMANAGE.
      Vertex beat Merck--even after starting 4 weeks delay in FDA approval-gaining 75% Market share in 5 months.
      Same thing happened with Omacor/Lovaza--Sales grew 100% to reach 341 mil.$ in 9months of 2007. GSK Press release says that the growth was 62% over same period of 2006.
      By the time GSK took over in 2008(as purchase happened on Nov.21,2007), Lovaza sales were 500 mil.$.
      GSK grew it from 500 to 900 mil.$ in 4 years to 900 mil.$.
      Pronova--owner of patents was able to grow sales to 500mil.$ in other countries. Total sales in 2011--GSK(Lovaza) + Omacor in Europe =900+500$=1400mil.$

0.9040.000(0.00%)Oct 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.